Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1844-1850

  Zobell, Jeffery T ^a,b   Stockmann, Chris ^c,e   Young, David C ^d   Cash, Jared ^a   McDowell, Brittany J ^c   Korgenski, Kent ^e,f   Sherwin, Catherine M T ^c   Spigarelli, Michael ^c   Chatfield, Barbara A ^b   Ampofo, Krow ^e  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b Intermountain Cystic Fibrosis Pediatric Center   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

Antibiotics; Cystic fibrosis; Pediatrics; Pharmacodynamics; Ticarcillin clavulanate

Indexed keywords

CLAVULANIC ACID; TICARCILLIN;

ADOLESCENT; ARTICLE; BACTERICIDAL ACTIVITY; CHILD; CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CLAVULANIC ACIDS; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; TICARCILLIN;

EID: 82855162711     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.010     Document Type: Article

References (22)

1. Timentin [package insert] 2010, GlaxoSmithKline, Research Triangle Park, NC.
2. Flume P.A., Mogayzel P.J., Robinson K.A., et al. Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Resp Crit Care Med 2009, 180:802-808.
3. Zobell J.T., Ampofo K., Cash J., et al. High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. J Cyst Fibros 2010, 9:280-283.
4. Arnoff SC, Beall RJ, Burns JL et al. Microbiology and infectious disease in cystic fibrosis. Cystic Fibrosis Foundation Consensus Conference, May 17-18, 1994, Bethesda, MD; Volume V, Section I.
5. Kliegman R., Behrman R.E., Jenson H.B., Stanton B.F. Nelson Textbook of Pediatrics 2007, 1119. Elsevier, Philadelphia, 1182. 18th ed.
6. Takemoto C.K., Hodding J.H., Kraus D.M. Pediatric Dosage Handbook 2010, Lexi-Comp, Inc, Hudson, OH.
7. de Groot R., Hack B.D., Weber A., et al. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin Pharmacol Ther 1990, 47:73-78.
8. Cumulative Antimicrobial Susceptibility Test (Antibiogram) Data Report 2010, Primary Children's Medical Center Microbiology Laboratory.
9. Williamson R., Tomasz A. Inhibition of cell wall synthesis and acylation of the penicillin binding proteins during prolonged exposure of growing Streptococcus pneumoniae to benzylpenicillin. Eur J Biochem 1985, 151:475-483.
10. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10. quiz 1-2.
11. Leggett J.E., Ebert S., Fantin B., Craig W.A. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1990, 74(Suppl):179-184.
12. Burgess D.S., Frei C.R. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 2005, 56:893-898.
13. Jusko W.J., Mosovich L.L., Gerbracht L.M., et al. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 1975, 56:1038-1044.
14. Yaffe S.J., Gerbracht L.M., Mosovich L.L., et al. Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis 1977, 135:828-831.
15. Jacobs R.F., Trang J.M., Kearns G.L., et al. Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. J Pediatr 1985, 106:1001-1007.
16. th informational supplement. CLSI/NCCLS M100-S20 2010, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, PA.
17. Schwartz G.J., Muñoz A., Schneider M.F. New equations to estimate GFR in children with CKD. Am Soc Nephrol 2009, 20:629-637.
18. Bulitta J.B., Duffull S.B., Kinzig-Schippers M., et al. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007, 51:2497-2507.
19. Bulitta J.B., Landersdorfer C.B., Huttner S.J., et al. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2010, 54:1275-1282.
20. Vinks A.A., van Rossem R.N., Mathot R.A., et al. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob Agents Chemother 2007, 51:3049-3055.
21. Mouton J.W., Punt N., Vinks A.A. A retrospective analysis using Monte Carlo simulation evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005, 27:762-772.
22. Alou L., Aguilar L., Sevillano D., et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa?. An in vitro pharmacodynamic model. J Antimicrob Chemother 2005, 55:209-213.